Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications

Abstract

Compositions and methods for treating or preventing a condition related to myocardial infarction and infarct expansion, extension, and/or dilation following a cardiovascular disorder incident (e.g., post-myocardial infarction) using an effective amount of RRx-001, or a pharmaceutically acceptable salt thereof, are described. In some embodiments, an agent (such as a statin, an angiotension-converting-enzyme (ACE) inhibitor, aspirin, oxygen, a nitric oxide donor, a drug-eluting stent, an anticoagulant or antiplatelet therapy, a phosphodiesterase-5 inhibitor, a calcium channel blocker, an angiotensin II receptor blocker (ARB), a beta blocker, an aldosterone antagonist, a loop diuretic, an epigenetic inhibitor, and/or a nitrite) is administered prior to, concurrently with, or subsequent administering the effective amount of RRx-001, or a pharmaceutically acceptable salt thereof. In some embodiments, the effective amount of RRx-001, or a pharmaceutically acceptable salt thereof, is administered as a composition comprising a blood product and/or the agent.

Dependencies are inferred from the claim text.